Skip to content
Vaccine Formulation Institute Logo
  • Activities
    • Supporting vaccine community with adjuvant and formulation expertise

      Academia

      Supporting vaccine community with adjuvant and formulation expertise

      Supporting adjuvanted vaccine development up to industrial scale

      Industry

      Supporting adjuvanted vaccine development up to industrial scale

      Helping donors and funders carry out vaccine development programs

      Funders

      Helping donors and funders carry out vaccine development programs

      • Activities
      • SWE adjuvant
  • About Us
    • Open-acess adjuvants and vaccine formulations for Global Health

      • Not-for-profit
      • History
      • Careers
  • News
  • Publications
  • Contact
  • Activities
    • Supporting vaccine community with adjuvant and formulation expertise

      Academia

      Supporting vaccine community with adjuvant and formulation expertise

      Supporting adjuvanted vaccine development up to industrial scale

      Industry

      Supporting adjuvanted vaccine development up to industrial scale

      Helping donors and funders carry out vaccine development programs

      Funders

      Helping donors and funders carry out vaccine development programs

      • Activities
      • SWE adjuvant
  • About Us
    • Open-acess adjuvants and vaccine formulations for Global Health

      • Not-for-profit
      • History
      • Careers
  • News
  • Publications
  • Contact

Publications

SQ adjuvant

  • All (49)
  • COVID-19 (1)
  • LMQ adjuvant (8)
  • LQ adjuvant (10)
  • SQ adjuvant (4)
  • SWE adjuvant (19)

Enhancing Immunogenicity of a Thermostable, Efficacious SARS-CoV-2 Vaccine Formulation through Oligomerization and Adjuvant Choice

  • All
  • /LMQ adjuvant
  • /LQ adjuvant
  • /SQ adjuvant
  • /SWE adjuvant
Khan MS, Jakob V, Singh R, et al. Published online December 12, 2023. doi:10.3390

Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen

  • All
  • /LMQ adjuvant
  • /LQ adjuvant
  • /SQ adjuvant
  • /SWE adjuvant

Doss-Gollin S, Thomas S, Brook B, et al. npj Vaccines. 2023;8(1):163. doi:10.1038/s41541-023-00759-y

OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model

  • All
  • /SQ adjuvant
Primard C, Monchâtre-Leroy E, Del Campo J, et al.  Front Immunol. 2023;14:1188605. doi:10.3389/fimmu.2023.1188605

Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models.

  • All
  • /LMQ adjuvant
  • /LQ adjuvant
  • /SQ adjuvant

Su J, Brunner L, Oz EA, et al. Journal of Hepatology. Published online January 2023:S0168827822034651. doi:10.1016/j.jhep.2022.12.013

VFI headquarters and Geneva laboratories

Rue du Champ-Blanchod 4
1228 Plan-les-Ouates
Switzerland

VFI Lausanne laboratories

Route de la Corniche 5
1066 Epalinges
Switzerland

contact@vformulation.org
VFI on LinkedIn
  • Home
  • Contact
  • Imprint
  • Privacy Policy

© 2025 Vaccine Formulation Institute